<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04880928</url>
  </required_header>
  <id_info>
    <org_study_id>Mydriasis with Mydrane</org_study_id>
    <nct_id>NCT04880928</nct_id>
  </id_info>
  <brief_title>Comparison Mydriasis by Mydrane With Topical Drop Application</brief_title>
  <official_title>Prospective Intraindividual Comparison of the Mydriasis of a Standardized Intracameral Anaesthetics With the Topical Preoperative Drop Application in the Uncomplicated Cataract Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Graz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Graz</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary aim of the study is to compare the effectiveness of the intracameral application&#xD;
      of MydraneÂ® (standardized combination of Tropicamide 0.02%, Phenylephrine 0.31% and Lidocaine&#xD;
      1%) with the preoperative topical application (Tropicamide 0.5% and Phenylephrine 10%). To&#xD;
      evaluate the steadiness of the dilating effect on the pupil, the ratio of eyes without&#xD;
      necessity for further pupil dilating procedures to perform the capsulorhexis is assessed.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 12, 2020</start_date>
  <completion_date type="Actual">September 23, 2021</completion_date>
  <primary_completion_date type="Actual">September 23, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>pupil dilating</measure>
    <time_frame>during first and second surgery: a maximum of four weeks between first and second surgery</time_frame>
    <description>The frequency of the feasibility of capsulorhexis without additional pupil dilating actions</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>subjective highest intraoperative pain</measure>
    <time_frame>after first and second surgery: a maximum of four weeks between first and second surgery</time_frame>
    <description>Highest intraoperative pain visualized on a visual analogue scale (VAS) asked by a questionnaire, with the minimum 1 and maximum 10 , where higher scores mean a worse outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>subjective perception of anesthetic procedures</measure>
    <time_frame>after first and second surgery: a maximum of four weeks between first and second surgery</time_frame>
    <description>perception of anesthetic procedures visualized on a visual analogue scale (VAS) asked by a questionnaire, with the minimum 1 and maximum 10 , where higher scores mean a worse outcome</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Cataract</condition>
  <arm_group>
    <arm_group_label>injection solution</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mydrane, Tropicamid 0,02%, Phenylephrine 0,31%, Lidocain 1%, injection solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard eye Drops</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Phenylephrine 10% and Tropicamid 0,5% eye drops</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eye injection (Mydrane)</intervention_name>
    <description>Mydrane 0.2 mg/ml + 3.1 mg/ml&#xD;
+ 10 mg/ml solution for injection tropicamide / phenylephrine hydrochloride / lidocaine hydrochloride</description>
    <arm_group_label>injection solution</arm_group_label>
    <other_name>Mydrane</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>eye drops (Phenylephrin)</intervention_name>
    <description>Phenylephrine 10%</description>
    <arm_group_label>Standard eye Drops</arm_group_label>
    <other_name>Minims</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>eye drops (Tropicamid)</intervention_name>
    <description>Tropicamid 0,5%</description>
    <arm_group_label>Standard eye Drops</arm_group_label>
    <other_name>Agepha</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and female patients between the age of 50 to 100 years&#xD;
&#xD;
          -  Day-hospital and inpatient care&#xD;
&#xD;
          -  Clinically significant opacity of the lens with indication for cataract surgery on&#xD;
             both eyes&#xD;
&#xD;
          -  Lack of previous ophthalmic surgeries&#xD;
&#xD;
          -  Lack of relevant ophthalmic conditions: Pseudoexfoliation syndrome, eye injuries,&#xD;
             present inflammation (in terms of uveitis, endophthalmitis and iridocyclitis),&#xD;
             restricted mydriasis (pupil diameter below 7mm after application of tropicamide 0.38%&#xD;
             and phenylephrine HCL 2.5% - at preoperative examination), elevated intraocular&#xD;
             pressure, alpha-receptor inhibitor intake (e.g. tamsulosin) due to impeded mydriasis&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Allergic to phenylephrine, tropicamide, sodium metabisulfite, disodium edetate, sodium&#xD;
             hydroxide, hydrochloric acid, lidocaine hydrochloride, sodium chloride, disodium&#xD;
             phosphate dodecahydrate, disodium phosphate dihydrate&#xD;
&#xD;
          -  Allergic to anesthesia (amide type)&#xD;
&#xD;
          -  Allergic to atropine derivates&#xD;
&#xD;
          -  Heart disease, tachycardia, hypertensive crises&#xD;
&#xD;
          -  Aneurism of big vessels&#xD;
&#xD;
          -  Untreated hyperthyroidism&#xD;
&#xD;
          -  Untreated closed angle glaucoma and narrow angles with tendencies to glaucoma by&#xD;
             intake of mydriatic drugs&#xD;
&#xD;
          -  Pregnancy, breast feeding and premenopausal women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Medical University Graz</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>May 5, 2021</study_first_submitted>
  <study_first_submitted_qc>May 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 11, 2021</study_first_posted>
  <last_update_submitted>October 11, 2021</last_update_submitted>
  <last_update_submitted_qc>October 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
    <mesh_term>Mydriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ophthalmic Solutions</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

